Warnings, Columns-Drugs & Supplements, November 2005
November 3, 2005
Eli Lilly and Centocor Discontinue ReoPro Clinical Trial HORSHAM, Pa. - Centocor Inc. and Eli Lilly & Co. have permanently discontinued patient enrollment in phase 3 of its ReoPro® (abciximab) clinical trial. ReoPro was under clinical trial for the treatment of acute ischemic stroke. The trial's independent Safety and Efficacy Monitoring Committee (SEMC) for the Abciximab in Emergent Stroke Treatment Trial-II recommended that the study discontinue enrollment, Eli Lilly and Centocor said, noting they agreed with the recommendation. Eli Lilly and Centocor temporarily suspended enrollment on Oct. 4, following a safety concern raised by the …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation ConferenceJanuary 10, 2025 - Long Beach, CA
The Westin Long Beach
|
